Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy - PubMed (original) (raw)

Review

doi: 10.1038/nrd3184.

Affiliations

Review

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Klaus Strebhardt. Nat Rev Drug Discov. 2010 Aug.

Abstract

The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of critical cell cycle events. Because PLK1 has been preclinically validated as a cancer target, small-molecule inhibitors of PLK1 have become attractive candidates for anticancer drug development. Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumour suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals. In this article, recent insights into the biology of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-molecule PLK1 inhibitors will be examined.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Oncogene. 2002 Sep 26;21(43):6633-40 - PubMed
    1. Eur J Pharmacol. 2008 Sep 4;591(1-3):102-5 - PubMed
    1. Cancer Res. 2006 Nov 1;66(21):10253-7 - PubMed
    1. Cell Cycle. 2006 Apr;5(8):853-64 - PubMed
    1. Bioorg Med Chem. 2007 Jan 15;15(2):800-14 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources